|
Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC). |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - Ipsen |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Accuray (Inst); AstraZeneca (Inst); Bayer (Inst); Cambridge Major Laboratories (Inst); Kyowa Hakko Kirin (Inst); Sanofi (Inst) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; Sanofi |
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals |
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Sanofi |
| |
|
Honoraria - Astellas Pharma; Janssen; Sanofi; Takeda |
Consulting or Advisory Role - Astellas Pharma; Bayer; Curevac; Dendreon; Ipsen; Janssen Oncology; Novartis; Orion; Sanofi; Takeda |
Travel, Accommodations, Expenses - Amgen |
| |
|
Honoraria - Astellas Pharma; Bayer; Janssen; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Sanofi |
| |
|
|
| |
|
|
| |
|
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi |
Research Funding - AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst) |
Patents, Royalties, Other Intellectual Property - Abiraterone Rewards to Inventors (Inst); PARP inhibitors and DNA repair defects (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Genmab; GlaxoSmithKline; Orion; Qiagen; Sanofi; Taiho Pharmaceutical; Vertex |